



## TECHNOLOGY

# Genetically Engineered Newcastle Disease Virus as an Oncolytic Agent

## OVERVIEW

Oncolytic viruses are state of the art for treatment of cancer. Presently non engineered strains of the New castle disease virus are being used in Phase I clinical trial for oncolysis.

Researchers at the University of Maryland have developed techniques that offer flexibility to engineer additional therapeutic transgenes in NDV genomes for enhancing the oncolytic efficacy. Additionally, it also enables targeted delivery of the recombinant NDV to specific site in the human body.

For additional information please contact Gayatri Varma at the Office of Technology Commercialization, University of Maryland. Phone: 301-405-2960. E-mail: [gayatri@umd.edu](mailto:gayatri@umd.edu)

## CONTACT INFO

UM Ventures  
0134 Lee Building  
7809 Regents Drive  
College Park, MD 20742  
Email: [umdtechtransfer@umd.edu](mailto:umdtechtransfer@umd.edu)  
Phone: (301) 405-3947 | Fax: (301) 314-9502

## Additional Information

### INSTITUTION

University of Maryland, College Park

### PATENT STATUS

Patent(s) pending

### LICENSE STATUS

Contact OTC for licensing information

### CATEGORIES

- Vaccines
- Platforms

### EXTERNAL RESOURCES

- [US Patent 9,803,216](#)

LS-2005-041